ATN 161

Drug Profile

ATN 161

Alternative Names: Ac-PHSCN-NH2

Latest Information Update: 05 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Attenuon LLC
  • Developer Attenuon; Tactic Pharma
  • Class Antineoplastics; Peptides
  • Mechanism of Action Angiogenesis inhibitors; Integrin alpha 5 beta 1 inhibitors; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioma; Renal cancer

Most Recent Events

  • 04 Feb 2016 Discontinued - Phase-I/II for Glioma (Recurrent) in USA (IV) before February 2016
  • 04 Feb 2016 Discontinued - Phase-II for Renal cancer in USA (IV) before February 2016
  • 31 May 2008 No development reported - Phase-I/II for Glioma (Recurrent) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top